PPM1D-truncating mutations confer resistance to chemotherapy and sensitivity to PPM1D inhibition in hematopoietic cells
Authors:
Top Cited Papers
Open Access
- 13 September 2018
- journal article
- research article
- Published by American Society of Hematology in Blood
- Vol. 132 (11) , 1095-1105
Abstract
Key Points: Truncating PPM1D mutations confer chemotherapy resistance, leading to the selective expansion of PPM1D-mutant cells in vitro and in vivo. PPM1D inhibitor treatment reverses the chemotherapy-resistance phenotype and selectively kills PPM1D-mutant cells.Keywords
This publication has 34 references indexed in Scilit:
- Ischemia in Tumors Induces Early and Sustained Phosphorylation Changes in Stress Kinase Pathways but Does Not Affect Global Protein LevelsMolecular & Cellular Proteomics, 2014
- Allosteric Wip1 phosphatase inhibition through flap-subdomain interactionNature Chemical Biology, 2014
- Gain-of-function mutations of PPM1D/Wip1 impair the p53-dependent G1 checkpointJournal of Cell Biology, 2013
- Sensitive detection of somatic point mutations in impure and heterogeneous cancer samplesNature Biotechnology, 2013
- Mosaic PPM1D mutations are associated with predisposition to breast and ovarian cancerNature, 2012
- Tiling Path Genomic Profiling of Grade 3 Invasive Ductal Breast CancersClinical Cancer Research, 2009
- PPM1D Is a Potential Therapeutic Target in Ovarian Clear Cell CarcinomasClinical Cancer Research, 2009
- The type 2C phosphatase Wip1: An oncogenic regulator of tumor suppressor and DNA damage response pathwaysCancer and Metastasis Reviews, 2008
- Mitochondria primed by death signals determine cellular addiction to antiapoptotic BCL-2 family membersCancer Cell, 2006
- Amplification of PPM1D in human tumors abrogates p53 tumor-suppressor activityNature Genetics, 2002